From bugs to drugs: Bacterial 3-IAA enhances efficacy of chemotherapy in pancreatic cancer
- PMID: 37196631
- PMCID: PMC10213830
- DOI: 10.1016/j.xcrm.2023.101039
From bugs to drugs: Bacterial 3-IAA enhances efficacy of chemotherapy in pancreatic cancer
Abstract
Tintelnot et al.1 identified enrichment of indole-3-acetic acid (3-IAA), a tryptophan metabolite produced by gut microbiota, as a predictor of chemotherapy response in pancreatic adenocarcinoma. Recapitulated in mouse models, 3-IAA represents a novel potential therapeutic approach for chemotherapy sensitization.
Published by Elsevier Inc.
Conflict of interest statement
Declaration of interests J.A.W. is an inventor on a US patent application (PCT/US17/53.717); reports compensation for speaker’s bureau and honoraria from Imedex, Dava Oncology, Omniprex, Illumina, Gilead, PeerView, MedImmune, and Bristol-Myers Squibb; serves as a consultant/advisory board member for Roche/Genentech, Novartis, AstraZeneca, GlaxoSmithKline, Bristol-Myers Squibb, Merck, Biothera Pharmaceuticals, and Micronoma. J.A.W. holds stock options from Micronoma.
Figures
Comment on
-
Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer.Nature. 2023 Mar;615(7950):168-174. doi: 10.1038/s41586-023-05728-y. Epub 2023 Feb 22. Nature. 2023. PMID: 36813961 Free PMC article.
References
-
- Conroy T., Hammel P., Hebbar M., Ben Abdelghani M., Wei A.C., Raoul J.L., Chone L., Francois E., Artru P., Biagi J.J., et al. FOLFIRINOX or gemcitabine as Adjuvant therapy for pancreatic cancer. N. Engl. J. Med. 2018;379:2395–2406. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
